297 related articles for article (PubMed ID: 18540668)
1. Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Sarver RW; Bills E; Bolton G; Bratton LD; Caspers NL; Dunbar JB; Harris MS; Hutchings RH; Kennedy RM; Larsen SD; Pavlovsky A; Pfefferkorn JA; Bainbridge G
J Med Chem; 2008 Jul; 51(13):3804-13. PubMed ID: 18540668
[TBL] [Abstract][Full Text] [Related]
2. Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Park WK; Kennedy RM; Larsen SD; Miller S; Roth BD; Song Y; Steinbaugh BA; Sun K; Tait BD; Kowala MC; Trivedi BK; Auerbach B; Askew V; Dillon L; Hanselman JC; Lin Z; Lu GH; Robertson A; Sekerke C
Bioorg Med Chem Lett; 2008 Feb; 18(3):1151-6. PubMed ID: 18155906
[TBL] [Abstract][Full Text] [Related]
3. Structural mechanism for statin inhibition of HMG-CoA reductase.
Istvan ES; Deisenhofer J
Science; 2001 May; 292(5519):1160-4. PubMed ID: 11349148
[TBL] [Abstract][Full Text] [Related]
4. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Istvan ES
Am Heart J; 2002 Dec; 144(6 Suppl):S27-32. PubMed ID: 12486413
[TBL] [Abstract][Full Text] [Related]
5. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
Zhang QY; Wan J; Xu X; Yang GF; Ren YL; Liu JJ; Wang H; Guo Y
J Comb Chem; 2007; 9(1):131-8. PubMed ID: 17206841
[TBL] [Abstract][Full Text] [Related]
6. Binding thermodynamics of statins to HMG-CoA reductase.
Carbonell T; Freire E
Biochemistry; 2005 Sep; 44(35):11741-8. PubMed ID: 16128575
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
Pfefferkorn JA; Song Y; Sun KL; Miller SR; Trivedi BK; Choi C; Sorenson RJ; Bratton LD; Unangst PC; Larsen SD; Poel TJ; Cheng XM; Lee C; Erasga N; Auerbach B; Askew V; Dillon L; Hanselman JC; Lin Z; Lu G; Robertson A; Olsen K; Mertz T; Sekerke C; Pavlovsky A; Harris MS; Bainbridge G; Caspers N; Chen H; Eberstadt M
Bioorg Med Chem Lett; 2007 Aug; 17(16):4538-44. PubMed ID: 17574412
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA).
Thilagavathi R; Kumar R; Aparna V; Sobhia ME; Gopalakrishnan B; Chakraborti AK
Bioorg Med Chem Lett; 2005 Feb; 15(4):1027-32. PubMed ID: 15686906
[TBL] [Abstract][Full Text] [Related]
9. Explaining statin inhibition effectiveness of HMG-CoA reductase by quantum biochemistry computations.
da Costa RF; Freire VN; Bezerra EM; Cavada BS; Caetano EW; de Lima Filho JL; Albuquerque EL
Phys Chem Chem Phys; 2012 Jan; 14(4):1389-98. PubMed ID: 22159045
[TBL] [Abstract][Full Text] [Related]
10. Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
Bratton LD; Auerbach B; Choi C; Dillon L; Hanselman JC; Larsen SD; Lu G; Olsen K; Pfefferkorn JA; Robertson A; Sekerke C; Trivedi BK; Unangst PC
Bioorg Med Chem; 2007 Aug; 15(16):5576-89. PubMed ID: 17560788
[TBL] [Abstract][Full Text] [Related]
11. Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone.
Pak VV; Koo M; Kim MJ; Yun L; Kwon DY
Bioorg Med Chem; 2008 Feb; 16(3):1309-18. PubMed ID: 17977732
[TBL] [Abstract][Full Text] [Related]
12. (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential.
Ahmad S; Madsen CS; Stein PD; Janovitz E; Huang C; Ngu K; Bisaha S; Kennedy LJ; Chen BC; Zhao R; Sitkoff D; Monshizadegan H; Yin X; Ryan CS; Zhang R; Giancarli M; Bird E; Chang M; Chen X; Setters R; Search D; Zhuang S; Nguyen-Tran V; Cuff CA; Harrity T; Darienzo CJ; Li T; Reeves RA; Blanar MA; Barrish JC; Zahler R; Robl JA
J Med Chem; 2008 May; 51(9):2722-33. PubMed ID: 18412317
[TBL] [Abstract][Full Text] [Related]
13. Specific inhibitions of annonaceous acetogenins on class II 3-hydroxy-3-methylglutaryl coenzyme A reductase from Streptococcus pneumoniae.
Feng L; Zhou L; Sun Y; Gui J; Wang X; Wu P; Wan J; Ren Y; Qiu S; Wei X; Li J
Bioorg Med Chem; 2011 Jun; 19(11):3512-9. PubMed ID: 21550257
[TBL] [Abstract][Full Text] [Related]
14. [Rosuvastatin: pharmacologic features].
Bernini F; Catapano AL
Ital Heart J; 2003 Dec; 4 Suppl 7():22S-32S. PubMed ID: 14983744
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
Chen JB; Chern TR; Wei TT; Chen CC; Lin JH; Fang JM
J Med Chem; 2013 May; 56(9):3645-55. PubMed ID: 23570542
[TBL] [Abstract][Full Text] [Related]
16. Peptide design of a competitive inhibitor for HMG-CoA reductase based on statin structure.
Pak VV; Kim SH; Koo M; Lee N; Shakhidoyatov KM; Kwon DY
Biopolymers; 2006; 84(6):586-94. PubMed ID: 16886212
[TBL] [Abstract][Full Text] [Related]
17. Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia.
da Silva VB; Taft CA; Silva CH
J Phys Chem A; 2008 Mar; 112(10):2007-11. PubMed ID: 18044855
[TBL] [Abstract][Full Text] [Related]
18. Pyrazole inhibitors of HMG-CoA reductase: an attempt to dramatically reduce synthetic complexity through minimal analog re-design.
Larsen SD; Poel TJ; Filipski KJ; Kohrt JT; Pfefferkorn JA; Sorenson RJ; Tait BD; Askew V; Dillon L; Hanselman JC; Lu GH; Robertson A; Sekerke C; Kowala MC; Auerbach BJ
Bioorg Med Chem Lett; 2007 Oct; 17(20):5567-72. PubMed ID: 17764936
[TBL] [Abstract][Full Text] [Related]
19. Peptide fragmentation as an approach in modeling of an active peptide and designing a competitive inhibitory peptide for HMG-CoA reductase.
Pak VV; Koo M; Kwon DY; Shakhidoyatov KM; Yun L
Bioorg Med Chem; 2010 Jun; 18(12):4300-9. PubMed ID: 20494585
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin.
Holdgate GA; Ward WH; McTaggart F
Biochem Soc Trans; 2003 Jun; 31(Pt 3):528-31. PubMed ID: 12773150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
